Who Is the Culprit? Tacrolimus vs. Thymoglobulin, A Rare Case of Thrombotic Microangiopathy After a Second Deceased Donor Kidney Transplant (DDKT) (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1170; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Her first transplant course consisted of alemtuzumab induction and complicated by membranous nephropathy and chronic antibody mediated rejection treated with rituximab leading to graft failure and CKD V. She was maintained on a triple tacrolimus/mycophenolate/prednisone regimen with taco levels around 5 heading into second transplant...Our case also highlights the potential confounding and inciting role thymoglobulin may play in endothelial injury which along with complement activation are primary pathways leading to de novo post-transplant TMA. Successful re-introduction of tacrolimus with close monitoring of renal function underscores the importance of individualizing immunosuppression in patients with high immune risk to preserve allograft function."
Clinical • Antibody-mediated Rejection • Chronic Kidney Disease • Glomerulonephritis • Hematological Disorders • Movement Disorders • Thrombocytopenia • Transplantation • HP
|
|
Aqsa Pervez; Abdelhadi Farouji; Rehan Ansari; Anita K. Patel; Sherif Metwally; Pritika Shrivastava; Rohini Prashar
|